By Mill Chart
Last update: Apr 17, 2024
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Ticker | Change | Comment |
---|---|---|
INVO | 89.47% | INVO BIOSCIENCE INC's (NASDAQ:INVO) shares rose 89.47% to $1.44 during Wednesday's pre-market session. The stock is trading 25.49% lower than a month ago. |
WISA | 64.59% | WISA TECHNOLOGIES INC's (NASDAQ:WISA) stock price increased by 64.59% to $10.04. The upward trend from yesterday's 249.0% gain continues in today's pre-market session, reflecting sustained positive performance for NASDAQ:WISA. A press release (Exploring Stock Surges: Key Insights, Noteworthy BUZZ: KAVL, PRSO, DYAI, WISA, JAGX) was released yesterday. |
AGFY | 56.09% | During Wednesday's pre-market session, AGRIFY CORP (NASDAQ:AGFY) experienced a 56.09% increase, with the stock price reaching $0.47. Two days ago the company had a press release: Agrify Corporation Reports Full-Year 2023 Earnings. |
EDBL | 49.45% | EDIBLE GARDEN AG INC (NASDAQ:EDBL) rose 49.45% to $6.8 during Wednesday's pre-market session. Despite the -13.33% decrease in share value just yesterday, today's pre-market session for NASDAQ:EDBL demonstrates a notable recovery, instilling renewed confidence. Earlier today the company had a press release: Edible Garden Reports Preliminary First Quarter Year-Over-Year Increase in Produce Revenues of 40%; Cut Herb Revenue Increased More Than 200% for the Same Period. |
MAPSW | 35.7% | WM TECHNOLOGY INC-CW24's (NASDAQ:MAPSW) stock price increased by 35.7% to $0.07. Following a -18.4% loss in the previous session, NASDAQ:MAPSW displays significant price volatility in today's pre-market session. |
VNDA | 32.13% | VANDA PHARMACEUTICALS INC's (NASDAQ:VNDA) stock price is advancing with 32.13% to a price of $5.35. The stock is trading 36.22% lower than a year ago. |
PLCE | 27.71% | CHILDREN'S PLACE INC/THE's (NASDAQ:PLCE) shares surged 27.71% to reach $9.08 during the pre-market session on Wednesday. In the last month the stock lost 45.93%. |
GRTX | 21.24% | GALERA THERAPEUTICS INC (NASDAQ:GRTX) rose 21.24% to $0.21 during Wednesday's pre-market session. This is a continuation of yesterday's gain of 11.18%. |
GPAK | 21.01% | GAMER PAKISTAN INC's (NASDAQ:GPAK) shares rose 21.01% to $0.34. This is a continuation of yesterday's gain of 11.34%. |
IMCC | 17.99% | IM CANNABIS CORP's (NASDAQ:IMCC) shares surged 17.99% to reach $0.61 during the pre-market session on Wednesday. Prices are quite volatile here as yesterday NASDAQ:IMCC closed with a -10.86% loss. |
Our premarket gainers page will show you the full list.
Ticker | Change | Comment |
---|---|---|
TMQ | -25.83% | TRILOGY METALS INC's (NYSEARCA:TMQ) shares fell 25.83% to $0.37. |
LGVN | -24.93% | Despite yesterday's decline, LONGEVERON INC-A (NASDAQ:LGVN) experienced a further 24.93% decrease in share price during Wednesday's pre-market session, reaching $2.65. After a strong performance yesterday with a 20.48% gain, NASDAQ:LGVN shows signs of retracement with a 24.93% decline in today's pre-market session. |
HUBC | -22.58% | The pre-market session on Wednesday witnessed a 22.58% decrease in HUB CYBER SECURITY LTD's (NASDAQ:HUBC) shares, with the stock price falling to $1.44. The stock is trading 82.35% higher than a month ago. |
DYNT | -18.18% | The pre-market session on Wednesday witnessed a 18.18% decrease in DYNATRONICS CORP's (NASDAQ:DYNT) shares, with the stock price falling to $0.45. Yesterday's significant 48.49% gain in NASDAQ:DYNT is met with a 18.18% decline in today's pre-market session, reflecting a shift in market sentiment. |
SAGE | -18.11% | Despite yesterday's decline, SAGE THERAPEUTICS INC (NASDAQ:SAGE) experienced a further 18.11% decrease in share price during Wednesday's pre-market session, reaching $12.8. A press release (Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease) was released earlier today. |
TPET | -18.02% | TRIO PETROLEUM CORP's (NYSEARCA:TPET) stock price is declining with 18.02% to a price of $0.4. The downward trend from yesterday's -22.56% drop persisted in today's pre-market session, with another decline of 18.02% for NYSEARCA:TPET. |
DFLI | -17.79% | The pre-market session on Wednesday witnessed a 17.79% decrease in DRAGONFLY ENERGY HOLDINGS CO's (NASDAQ:DFLI) shares, with the stock price falling to $0.51. Following yesterday's gain of 36.51%, NASDAQ:DFLI experiences a 17.79% decrease in today's pre-market session, indicating a pullback from the previous session's performance. A press release (Dragonfly Energy Reports Fourth Quarter 2023 and Full Year Financial Results) was released two days ago. |
IZM | -15.93% | The pre-market session on Wednesday witnessed a 15.93% decrease in ICZOOM GROUP INC -CLASS A's (NASDAQ:IZM) shares, with the stock price falling to $42.89. In the last month the share price increased with 461.0%. |
OTRK | -15.85% | ONTRAK INC's (NASDAQ:OTRK) shares experienced a 15.85% decline, falling to $0.39 during Wednesday's pre-market session. Yesterday the company had a press release: Ontrak Announces 2023 Fourth Quarter and Year End Financial Results. |
SPCB | -15.8% | The pre-market session on Wednesday witnessed a 15.8% decrease in SUPERCOM LTD's (NASDAQ:SPCB) shares, with the stock price falling to $0.31. In the last month the stock gained 129.0%. |
Our premarket losers page will show you the full list.
SAGE THERAPEUTICS INC
NASDAQ:SAGE (5/13/2024, 7:00:02 PM)
After market: 12.75 +0.59 (+4.81%)12.165
+0.26 (+2.23%)
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...
SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease. The PRECEDENT Study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42. WAIS-IV is the
Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases.